Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice

Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice

Background: There are no clinical studies comparing the efficacy of bevacizumab vs.aflibercept in association with folfiri in RAS mutated (RAS-M) metastatic colorectal cancer patients (mCRC) pretreated with folfox and bevacizumab.Patients and Methods: Consecutive RAS-M unresectable mCRC patients pro...

Full description

Bibliographic Details
Main Authors: Alessandro Ottaiano, Monica Capozzi, Salvatore Tafuto, Alfonso De Stefano, Chiara De Divitiis, Carmela Romano, Antonio Avallone, Guglielmo Nasti
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-08-01
Series:Frontiers in Oncology
Subjects:
colorectal cancer
chemotherapy
bevacizumab
aflibercept
real practice
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00766/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00766/full

Similar Items